BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rajasingham R, Enns EA, Khoruts A, Vaughn BP. Cost-effectiveness of Treatment Regimens for Clostridioides difficile Infection: An Evaluation of the 2018 Infectious Diseases Society of America Guidelines. Clin Infect Dis 2020;70:754-62. [PMID: 31001619 DOI: 10.1093/cid/ciz318] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 Jiang Y, Sarpong EM, Sears P, Obi EN. Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States. Infect Dis Ther 2021. [PMID: 34292496 DOI: 10.1007/s40121-021-00480-0] [Reference Citation Analysis]
2 Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, Stollman NH. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol 2021;116:1124-47. [PMID: 34003176 DOI: 10.14309/ajg.0000000000001278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Richardson M, Erman A, Daneman N, Miller FA, Sander B. Defining the decision problem: A scoping review of economic evaluations for Clostridioides difficile interventions. J Hosp Infect 2021:S0195-6701(21)00408-4. [PMID: 34813872 DOI: 10.1016/j.jhin.2021.11.010] [Reference Citation Analysis]
4 Hall RG, Cole TJ, Shaw C, Alvarez CA. The Risk of Clostridioides difficile Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts. Antibiotics 2022;11:295. [DOI: 10.3390/antibiotics11030295] [Reference Citation Analysis]
5 Luo Y, Lucas AL, Grinspan AM. Fecal Transplants by Colonoscopy and Capsules Are Cost-Effective Strategies for Treating Recurrent Clostridioides difficile Infection. Dig Dis Sci 2020;65:1125-33. [DOI: 10.1007/s10620-019-05821-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
6 Auchtung JM, Preisner EC, Collins J, Lerma AI, Britton RA. Identification of Simplified Microbial Communities That Inhibit Clostridioides difficile Infection through Dilution/Extinction. mSphere 2020;5:e00387-20. [PMID: 32727857 DOI: 10.1128/mSphere.00387-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
7 Mateu L, Fernández-Rivas G, Sopena N. Diagnosis and treatment of Clostridioides difficile infection. Med Clin (Barc) 2020;155:30-5. [PMID: 32430207 DOI: 10.1016/j.medcli.2020.02.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Mamoon L, Olesen SW. Fecal Microbiota Transplants Annually and Their Positive Clinical Impact. Clin Transl Gastroenterol 2020;11:e00247. [PMID: 33259159 DOI: 10.14309/ctg.0000000000000247] [Reference Citation Analysis]
9 Smith-Peter E, Séguin DL, St-Pierre É, Sekulovic O, Jeanneau S, Tremblay-Tétreault C, Lamontagne AM, Jacques PÉ, Lafontaine DA, Fortier LC. Inactivation of the riboswitch-controlled GMP synthase GuaA in Clostridioides difficile is associated with severe growth defects and poor infectivity in a mouse model of infection. RNA Biol 2021;:1-12. [PMID: 34612173 DOI: 10.1080/15476286.2021.1978768] [Reference Citation Analysis]
10 Okumura H, Ueyama M, Shoji S, English M. Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan. Journal of Infection and Chemotherapy 2020;26:611-8. [DOI: 10.1016/j.jiac.2020.01.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Lee HY, Hsiao HL, Chia CY, Cheng CW, Tsai TC, Deng ST, Chen CL, Chiu CH. Risk factors and outcomes of Clostridium difficile infection in hospitalized patients. Biomed J 2019;42:99-106. [PMID: 31130254 DOI: 10.1016/j.bj.2018.12.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
12 Sehgal K, Yadav D, Khanna S. The interplay of Clostridioides difficile infection and inflammatory bowel disease. Therap Adv Gastroenterol 2021;14:17562848211020285. [PMID: 34104215 DOI: 10.1177/17562848211020285] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Carlson TJ, Gonzales-luna AJ. Antibiotic Treatment Pipeline for Clostridioides difficile Infection (CDI): A Wide Array of Narrow-Spectrum Agents. Curr Infect Dis Rep 2020;22. [DOI: 10.1007/s11908-020-00730-1] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Khurana S, Kahl A, Yu K, DuPont AW. Recent advances in the treatment of Clostridioides difficile infection: the ever-changing guidelines. Fac Rev 2020;9:13. [PMID: 33659945 DOI: 10.12703/b/9-13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Gupta A, Ananthakrishnan AN. Economic burden and cost-effectiveness of therapies for Clostridiodes difficile infection: a narrative review. Therap Adv Gastroenterol 2021;14:17562848211018654. [PMID: 34104214 DOI: 10.1177/17562848211018654] [Reference Citation Analysis]
16 Cho JM, Pardi DS, Khanna S. Update on Treatment of Clostridioides difficile Infection. Mayo Clinic Proceedings 2020;95:758-69. [DOI: 10.1016/j.mayocp.2019.08.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
17 Oksi J, Anttila VJ, Mattila E. Treatment of Clostridioides (Clostridium) difficile infection. Ann Med 2020;52:12-20. [PMID: 31801387 DOI: 10.1080/07853890.2019.1701703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]